Fundamental Analysis of VIKING THERAPEUTICS INC(NASDAQ:VKTX) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to VKTX. VKTX was compared to 581 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VKTX as it has an excellent financial health rating, but there are worries on the profitability. VKTX has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

VKTX had negative earnings in the past year.

In the past year VKTX has reported a negative cash flow from operations.

VKTX had negative earnings in each of the past 5 years.

VKTX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With an excellent Return On Assets value of -9.69%, VKTX belongs to the best of the industry, outperforming 88.26% of the companies in the same industry.

VKTX has a better Return On Equity (-10.04%) than 90.67% of its industry peers.

		Industry Rank	Sector Rank
ROA	-9.69%
ROE	-10.04%
ROIC	N/A

ROA(3y)-30.09%

ROA(5y)-22.95%

ROE(3y)-33.1%

ROE(5y)-24.95%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

VKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VKTX has more shares outstanding than it did 1 year ago.

The number of shares outstanding for VKTX has been increased compared to 5 years ago.

VKTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

VKTX has an Altman-Z score of 121.74. This indicates that VKTX is financially healthy and has little risk of bankruptcy at the moment.

VKTX has a Altman-Z score of 121.74. This is amongst the best in the industry. VKTX outperforms 99.48% of its industry peers.

There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	121.74

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

VKTX has a Current Ratio of 29.48. This indicates that VKTX is financially healthy and has no problem in meeting its short term obligations.

VKTX has a better Current ratio (29.48) than 96.72% of its industry peers.

VKTX has a Quick Ratio of 29.48. This indicates that VKTX is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 29.48, VKTX belongs to the top of the industry, outperforming 96.72% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	29.48
Quick Ratio	29.48

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.11% over the past year.

EPS 1Y (TTM)2.11%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-4%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 34.21% on average over the next years. This is a very strong growth

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-23.97%

EPS Next 2Y-31.01%

EPS Next 3Y-20.39%

EPS Next 5Y34.21%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

VKTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VKTX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as VKTX's earnings are expected to decrease with -20.39% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-31.01%

EPS Next 3Y-20.39%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

VKTX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VIKING THERAPEUTICS INC

NASDAQ:VKTX (5/31/2024, 7:12:22 PM)

After market: 62.2 -0.06 (-0.1%)

62.26

+0.48 (+0.78%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap6.87B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-9.69%
ROE	-10.04%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	29.48
Quick Ratio	29.48
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)2.11%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-23.97%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

VIKING THERAPEUTICS INC (VKTX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens